Provider and Caregiver Connection: Understanding and Addressing the Effects of Pseudobulbar Affect on Patients' QoL

Released On
March 27, 2020

Expires On
March 27, 2021

Media Type

Completion Time
90 minutes

Neurology, Primary Care, Psychiatry

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Avanir Pharmaceuticals.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for neurologists, psychiatrists, nurse practitioners, physician assistants, and other health care professionals involved in the management of PBA.

Program Overview

Pseudobulbar affect is characterized by sudden and uncontrollable outbursts of crying or laughter that are out of context with an individual’s mood or situation. The psychological consequences around family members and in social situations can be substantial, leading to isolation and depression. As a relatively rare condition, PBA is frequently misdiagnosed or underdiagnosed. Underlying neurological conditions, most commonly multiple sclerosis, amyotrophic lateral sclerosis, stroke, and traumatic brain injuries, are associated with pseudobulbar affect. Although antidepressants have been used with little evidence to treat symptoms of PBA, the approved combination therapy of dextromethorphan hydrobromide/quinidine sulfate provides significant relief to patients with PBA.

To enable earlier diagnosis and treatment of pseudobulbar affect, this 2-part Provider and Caregiver Connection™ first provides expert audio commentary and text overview of clinical aspects of pseudobulbar affect. Patient and caregiver perspectives are then provided in a panel-style discussion with faculty who cover the burden on quality of life, challenges of diagnosis, and effective treatment.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Delineate the key symptoms of PBA and its burden on patients and their caregivers
  • Diagnose PBA more promptly and accurately to enable earlier intervention
  • Evaluate the efficacy and safety of pharmacologic agents for use in patients with PBA
  • Develop evidence-based treatment strategies for individual patients with PBA to reduce symptoms and optimize outcomes


Gerald A. Maguire, MD

Professor and Chair
Psychiatry and Neuroscience
University of California, Riverside School of Medicine
Riverside, CA

William M. Sauvé, MD

Regional Medical Director
Greenbrook TMS NeuroHealth Centers
Richmond, VA

James Wymer, MD, PhD

Director, Neuromuscular Division
University of Florida
Gainesville, FL

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hour.

Disclosures of Conflicts of Interest

Gerald A. Maguire, MD

  • Grant/Research Support: Axsome, Otsuka, Teva, Intracellular, Emalex;
  • Consultant: Acadia, Emalex;
  • Speaker’s Bureau: Otsuka, Takeda, Janssen, Sunovion, Neurocrine, Teva.

William M. Sauvé, MD

  • Disclosures: no relevant financial relationships with commercial interests.

James Wymer, MD, PhD

  • Disclosures: no relevant financial relationships with commercial interests.

George Handgis (Patient Interviewee)

  • Disclosures: no relevant financial relationships with commercial interests.

Sharon Handgis (Caregiver Interviewee)

  • Disclosures: no relevant financial relationships with commercial interests.

Physicians’ Education Resource®, LLC (PER®), uses a blinded peer review process. The peer reviewer discloses the following:

  • Grant/Research Support: Biogen, Novartis;
  • Consultant: Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, Sanofi, Teva, and TG Therapeutics.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio/video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/ Audio/Videos” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.